文献
J-GLOBAL ID:202202226718554391
整理番号:22A1171304
ホルモン受容体陽性,ヒト上皮増殖因子受容体2陰性進行乳癌の男性患者におけるリボシクリブ+レトロゾール:第IIIb相補体1試験のサブグループ解析【JST・京大機械翻訳】
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
著者 (11件):
Campone Mario
(Western Cancer Institute, Nantes, France)
,
De Laurentiis Michelino
(Istituto Nazionale Tumori IRCCS “Fondazione Pascale”, Naples, Italy)
,
Zamagni Claudio
(IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy)
,
Kudryavcev Igor
(Kaluga Regional Clinical Oncology Center, Kaluga, Russian Federation)
,
Agterof Marieette
(St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands)
,
Brown-Glaberman Ursa
(University of New Mexico Cancer Center, Albuquerque, NM, USA)
,
Palacova Marketa
(Masaryk Memorial Cancer Institute, Brno, Czech Republic)
,
Chatterjee Sanjoy
(Tata Medical Center, Kolkata, India)
,
Menon-Singh Lakshmi
(Novartis Pharmaceuticals, East Hanover, NJ, USA)
,
Wu Jiwen
(Novartis Pharmaceuticals, East Hanover, NJ, USA)
,
Martin Miguel
(Gregorio Maranon General University Hospital, Madrid, Spain)
資料名:
Breast Cancer Research and Treatment
(Breast Cancer Research and Treatment)
巻:
193
号:
1
ページ:
95-103
発行年:
2022年
JST資料番号:
W4122A
ISSN:
1573-7217
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
ドイツ (DEU)
言語:
英語 (EN)